Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | SCN4A | P35499 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8799683 | 1.00 | CYP1A2 (0.63) | CYP1A2KMT2ASMN1; SMN2KCNH2CACNA1G | |
| SCHEMBL8798100 | 1.00 | CYP1A2 (0.63) | CYP1A2KMT2ASMN1; SMN2KCNH2CACNA1G | |
| SCHEMBL11127254 | 0.90 | SMN1; SMN2 (0.61) | CYP1A2KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL15450588 | 0.89 | CYP1A2 (0.60) | CYP1A2KMT2ASMN1; SMN2KCNH2CACNA1G | |
| SCHEMBL9922436 | 0.85 | CYP1A2 (0.59) | CYP1A2KMT2ASMN1; SMN2KCNH2CACNA1G | |
| SCHEMBL9922127 | 0.85 | CYP1A2 (0.59) | CYP1A2KMT2ASMN1; SMN2KCNH2CACNA1G | |
| SCHEMBL11140249 | 0.83 | CYP1A2 (0.66) | CYP1A2KMT2AKCNH2CACNA1GMAPK1 | |
| SCHEMBL20883372 | 0.83 | KMT2A (0.55) | CYP1A2KMT2ASMN1; SMN2KCNH2CACNA1G | |
| SCHEMBL6074194 | 0.82 | PTGS1 (0.57) | KMT2ASMN1; SMN2KCNH2MAPTTSHR | |
| SCHEMBL1496562 | 0.82 | CYP1A2 (0.60) | CYP1A2KMT2ASMN1; SMN2KCNH2CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-109689861-A | For treating the composition and method of acne | 加州大学评议会 | 2019-04-26 | — | — | CN | disclosed |
| CN-109562048-A | For promoting the composition and method of skin health | 加州大学评议会 | 2019-04-02 | — | — | CN | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-8063225-B2 | 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders | CHEMBRIDGE CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-5696140-A | FOR TREATMENT OF ASTHMA, ALLERGIES, NERVOUS SYSTEM DISORDERS OR CANCER | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1997-12-09 | — | — | US | disclosed |
| EP-0702015-B1 | Bicyclic oxazole and thiazole substituted ethers | CIBA GEIGY AG (CH) | 1997-09-24 | — | — | EP | disclosed |
| US-5563160-A | NERVOUS SYSTEM DISORDERS, ANTIHISTAMINE, ANTIALLERGENS | Leo Pharmaceutical Products Ltd. A/S (L.o slashed.vens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1996-10-08 | — | — | US | disclosed |
| CN-1130186-A | Ethers substituted by dicycle oxazole and thiazole | SANDOZ CO LTD (CH) | 1996-09-04 | — | — | CN | disclosed |
| EP-0660823-B1 | N-CYANO-N'-PYRIDYLGUANIDINES AS SEROTONIN ANTAGONISTS | LEO PHARM PROD LTD (DK) | 1996-08-14 | — | — | EP | disclosed |
| EP-0702015-A1 | Bicyclic oxazole and thiazole substituted ethers | SANDOZ LTD. (CH) | 1996-03-20 | — | — | EP | disclosed |
| EP-0660823-A1 | N-CYANO-N'-PYRIDYLGUANIDINES AS SEROTONIN ANTAGONISTS. | LEO PHARM PROD LTD (DK) | 1995-07-05 | — | — | EP | disclosed |
| WO-1994006770-A1 | N-CYANO-N'-PYRIDYLGUANIDINES AS SEROTONIN ANTAGONISTS | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1994-03-31 | — | — | WO | disclosed |
| EP-0522176-A1 | DIHYDROPYRIDINE COMPOUNDS, AND PROCESS FOR THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-01-13 | — | — | EP | disclosed |
| WO-1992013839-A1 | DIHYDROPYRIDINE COMPOUNDS, AND PROCESS FOR THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | CYP1A2 1089/4885KMT2A 2169/4885SMN1; SMN2 2866/4885 |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | CYP1A2 1089/4885KMT2A 2169/4885SMN1; SMN2 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.